Magnetic resonance imaging applications in the evaluation of tumor angiogenesis

Seminars in Radiation Oncology

Volumn 11, Issue 1, 2001, Pages 70-82

  Neeman, Michal ^a,b   Provenzale, James M ^a,b   Dewhirst, Mark W ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; BLOOD VESSEL FUNCTION; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL REACTIVITY; BLOOD VOLUME; CANCER; HUMAN; IN VIVO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR;

EID: 0035181988     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2001.18105     Document Type: Article

References (101)

1. Clinical applications of angiogenic growth factors and their inhibitors
2. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis
3. Blood vessel formation: What is its molecular basis?
4. New perspectives in clinical oncology from angiogenesis research
5. Tumoural vascularity as a prognostic factor in cancer patients: The evidence continues to grow
6. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy
7. Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models
8. Immunophenotype of intraductal carcinoma
9. Ductal carcinoma in situ: MR imaging-histopathologic correlation
10. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy
11. Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival
12. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
13. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis
14. Tissue transglutaminase expression in human breast cancer
15. Microenvironmental control of gene expression: Implications for tumor angiogenesis, progression, and metastasis
16. Angiogenesis and oxygen transport in solid tumors
17. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
18. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
19. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
20. Oxygenation predicts radiation response and survival in patients with cervix cancer
21. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix
22. Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels
23. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker
24. Early wound healing exhibits cytokine surge without evidence of hypoxia
25. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
26. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells
27. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor
28. Vascular endothelial growth factor (VEGF) and its receptors
29. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin
30. Autoregulation of angiogenesis by cells of the vessel wall
31. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy
32. Angiostatin binds ATP synthase on the surface of human endothelial cells
33. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis
34. Angiogenesis and blood flow in solid tumors
35. Fourier analysis of fluctuations of oxygen tension and blood flow in R 3230Ac tumors and muscle of rats
36. Perivascular oxygen tensions in a transplantable mammary tumor growing in a dorsal flap window chamber
37. Interstitial pH and pO2 gradients in solid tumors in vivo: High resolution measurements reveal a lack of correlation
38. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols
39. An exciting and challenging role for the advanced contrast MR imaging
40. Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging
41. MR imaging of tumor microcirculation: Promise for the new millennium
42. Dynamic imaging with lanthanide chelates in normal brain: Contrast due to magnetic susceptibility effects
43. Cerebral blood volume maps of gliomas: Comparison with tumor grade and histologic findings
44. Susceptibility contrast imaging of cerebral blood volume: Human experience
45. MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas
46. Measurement of cerebral mean transit time by dynamic susceptibility contrast magnetic resonance imaging
47. Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: A possible marker of vascular tortuosity
48. Angiogenic activity of cervical carcinoma: Assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome
49. Gd-enhanced dynamic magnetic resonance imaging of breast masses
50. Pathophysiologic basis of contrast enhancement in breast tumors
51. Effects of endocrine treatment on prostate morphology and vascular permeability evaluated by magnetic resonance imaging
52. Dynamic contrast enhanced MR imaging in the evaluation of antiangiogenesis therapy
53. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
54. Assessing tumor angiogenesis using macromolecular MR imaging contrast media
55. Comparison of gadopentetate dimeglumine and albumin-(Gd-DTPA) 30 for microvessel characterization in an intracranial glioma model
56. Mammary carcinoma model: Correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density
57. Tumor angiogenesis, vascularization, and contrast-enhanced magnetic resonance imaging
58. Steady-state and dynamic MR angiography with MS-325: Initial experience in humans
59. MS-325: Albumin-targeted contrast agent for MR angiography
60. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor
61. Treatment of experimental brain tumors with trombospondin-1 derived peptides: An in vivo imaging study
62. In vivo assessment of vascular endothelial growth factor-induced angiogenesis
63. Cervical carcinoma: Standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival
64. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
65. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis
66. NMR imaging of changes in vascular morphology due to tumor angiogenesis
67. On the characteristics of functional magnetic resonance imaging of the brain
68. Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging
69. Neovascularization induced growth of implanted C6 glioma multicellular spheroids: Magnetic resonance microimaging
70. Stimulation of tumour angiogenesis by proximal wounds: Spatial and temporal analysis by MRI
71. Stimulation of tumour growth by wound-derived growth factors
72. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma
73. Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice
74. Intercellular communication between vascular smooth muscle and endothelial cells mediated by heparin-binding epidermal growth factor-like growth factor and vascular endothelial growth factor
75. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis
76. The response of human tumors to carbogen breathing, monitored by gradient-recalled echo magnetic resonance imaging
77. Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging
78. Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing
79. Correlation of magnetic resonance and oxygen microelectrode measurements of carbogen-induced changes in tumor oxygenation
80. Spectroscopic imaging of the water resonance with short repetition time to study tumor response to hyperoxia
81. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1alpha
82. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
83. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha
84. Control of angiogenesis by the pericyte: Molecular mechanisms and significance
85. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VECF
86. In vivo prediction of vascular susceptibility to vascular endothelial growth factor withdrawal: Magnetic resonance imaging of C6 rat glioma in nude mice
87. The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice
88. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
89. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging
90. The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
91. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): A non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography
92. 19F NMR spectroscopy of hexafluorobenzene
93. Regional tumor oxygen tension: Fluorine echo planar imaging of hexafluorobenzene reveals heterogeneity of dynamics
94. 19F-MR relaxometry
95. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status
96. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: Downregulation of HGF in response to hypoxia in vascular cells
97. Possible protective role of growth hormone in hypoxia-ischemia in neonatal rats
98. Hypoxia-induced interleukin-6 and interleukin-8 production is mediated by platelet-activating factor and platelet-derived growth factor in primary human lung cells
99. Tumor hypoxia and heterogeneity: Challenges and opportunities for the future
100. Endothelial cell responses to hypoxic stress
101. Prostate cancer tumor grade differentiation with dynamic contrast-enhanced MR imaging in the rat: Comparison of macromolecular and small-molecular contrast media - Preliminary experience